Valneva Reports Positive Final Phase 2 Antibody Persistence
2 days ago · Saint-Herblain (France), December 10, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive final antibody …
Valneva Reports Positive Final Phase 2 Antibody Persistence and …
Saint-Herblain (France), December 10, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive final antibody persistence and …
Valneva Reports Positive Final Phase 2 Antibody Persistence
3 days ago · The primary and secondary objectives of the trial were to evaluate the safety and immunogenicity of two different dose levels of Valneva’s single-shot chikungunya vaccine.
Valneva reports data from chikungunya vaccine trial in children
Jun 6, 2025 · Valneva has reported encouraging six-month safety and antibody persistence data from the multi-centre Phase II trial, VLA1553-221, of its chikungunya vaccine, Ixchiq, in 304 …
Valneva (VALN) Reveals Positive Phase 2 Data for Chikungunya Vaccine
4 days ago · Valneva (VALN) has released encouraging final results from its Phase 2 clinical trial of the chikungunya vaccine candidate, IXCHIQ. The study, involving 304 children, assessed …
Valneva Reports Positive Final Phase 2 Antibody Persistence and …
3 days ago · Saint-Herblain (France), December 10, 2025 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive final antibody persistence …
Valneva Reports Positive Final Phase 2 Antibody Persistence and …
3 days ago · Saint-Herblain, France – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive final antibody persistence and safety …
VALN Press Release: Valneva Reports Positive Final Phase 2 Antibo...
4 days ago · Saint-Herblain (France), December 10, 2025 – Valneva SE (NASDAQ: VALN, PARIS: VLA), a specialty vaccine company, today announced positive final antibody …
Bavarian Nordic initiates trial of chikungunya vaccine in children …
Jun 13, 2025 · On June 12, a new phase 3 clinical study of the Vimkunya single-dose, virus-like particle (VLP) chikungunya vaccine was initiated by Bavarian Nordic A/S among children aged …
Valneva Reports Positive Six-Month Antibody Persistence and …
Jun 5, 2025 · VLA1553-221 is a multi-center, randomized, observer-blinded, dose response Phase 2 clinical trial in 304 healthy children aged one to eleven years. The trial is performed at …